The Impact of Gleason Grade 3 as a Predictive Factor for Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group).

Journal: Medicina (Kaunas, Lithuania)
Published Date:

Abstract

: This study's objective was to examine patients treated with robot-assisted radical prostatectomy (RARP) for intermediate-risk prostate cancer (IR-PCa), and to identify preoperative risk factors for biochemical recurrence (BCR) in these patients in Japan. : We conducted a retrospective multicenter cohort study of patients with PCa who underwent RARP at 10 institutions in Japan. A total of 3195 patients were enrolled in this study. We focused on patients with IR-PCa who underwent RARP. We obtained data on pre- and postoperative covariates from the enrolled patients. Biochemical recurrence-free survival was the primary endpoint of this study. We also identified useful preoperative predictive factors for BCR in patients with IR-PCa after RARP. : A total of 1144 patients with IR-PCa were enrolled in this study. The median follow-up period was 23.7 months. At the end of the follow-up period, 94 (8.2%) patients developed BCR. The 2 and 3 year biochemical recurrence-free survival (BRFS) rates were 92.2% and 90.2%, respectively. Using the Kaplan-Meier method, Gleason grade (GG) 3 was significantly associated with poor BRFS compared with ≤GG 2. In multivariate analysis, GG 3 was a significant predictive factor for BCR in patients with IR-PCa. : The results of the study indicated a significant relationship between GG 3 and post-RARP BCR in patients with IR-PCa.

Authors

  • Makoto Kawase
    Department of Urology, Gifu University Graduate School of Medicine, Gifu 5011194, Japan.
  • Shin Ebara
  • Tomoyuki Tatenuma
    Department of Urology, Kanagawa Cancer Center.
  • Takeshi Sasaki
    Department of Next-Generation Pathology Information Networking, Faculty of Medicine, The University of Tokyo.
  • Yoshinori Ikehata
    Department of Urology, University of Toyama, Toyama, Japan.
  • Akinori Nakayama
    Department of Urology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan.
  • Masahiro Toide
    Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
  • Tatsuaki Yoneda
    Department of Urology, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
  • Kazushige Sakaguchi
    Department of Urology, Toranomon Hospital, Tokyo, Japan.
  • Jun Teishima
    Department of Urology, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima, Japan.
  • Kazuhide Makiyama
    Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
  • Takahiro Inoue
    Department of Gastrointestinal Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan.
  • Hiroshi Kitamura
    Department of Urology, University of Toyama, Toyama, Japan.
  • Kazutaka Saito
    Department of Urology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan.
  • Fumitaka Koga
    Department of Urology, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan. f-koga@cick.jp.
  • Shinji Urakami
    Department of Urology, Toranomon Hospital, Tokyo, Japan.
  • Takuya Koie
    Department of Urology, Gifu University Graduate School of Medicine, Gifu 5011194, Japan.